CognixA developer of non-invasive technology of the brain computer interface (BCI), announced that BlackRock Neurotech, a company that manufactures an implantable BCIS, will provide an AXON-R portable neural interface platform in cognix to research institutions via its distribution network.
Blackrock Neurotech will act as a dispenser without restriction of the cognix axone-R, a non-invasive laptop which allows an exact measure and modulation of brain activity via visual stimuli, biofeedback and neurofeedback.
Axon-R is a level of research system intended exclusively for a use studied in neuroscience, educational use and neurorehabilitation. It is not eliminated by the FDA for clinical or therapeutic applications.
In a press release, BlackRock Neurotech said that its main objective will remain on the implantable and sovereign BCIs that restore speech, movement and sensation; However, he points out that the availability of research level tools, such as the Axon-R, opens the door to multidisciplinary innovation.
“This collaboration represents a powerful alignment of complementary technologies which will have a disproportionate impact in neurotechnology applications,” said Andreas Forsland, CEO of cognix, in a press release.
“Blackrock neurotech implant technology combined with cognix AI and augmented reality platform will open new doors to researchers and clinicians, while providing transformative solutions to individuals that we finally serve.”
Marcus Gerhardt, CEO of Blackrock Neurotech, said that his business’s mission was to restore capacity.
“By expanding access to level of research tools like Axon-R, we aim to support the early exploration of neural interfaces while maintaining our clinical focus on sovereign and implantable high fidelity technologies that restore speech, movement and sensation,” said Gerhardt in a press release.
The biggest trend
In March, Forsland de Cognixion maintained itself Himss TV Regarding the use of augmented reality, AI and interface technologies of the brain-computer to allow patients with traumatic brain lesions, stroke and SLA to communicate using their eyes.
In 2024, Noldus Information Technology collaborated with BlackRock Neurotech to integrate the behavioral monitoring software of Noldus Ethovision XT with BlackRock electrophysiology systems, creating a unified behavioral and neuronal research platform.
Integration allows real -time synchronization of Ethovision XT behavioral monitoring data with BlackRock EEG recordings for mice and rats.
The objective was to allow researchers to link neural activity in real time to behavioral results with greater precision and efficiency.
Other companies in the BCI space include Synchronouswho announced this week that it will be the First BCI company to achieve native integration with Apple Profile BCI Human Interface Device (BCI HID).
Company technology is intended to allow people to control digital devices, such as iphones, iPads and Apple Vision Pro, using their thoughts.
Earlier this month, Elon Musk Neural announced it implemented its brain interface In a man by the name of Brad Smith, who has a SLA and who is completely non -verbal, allowing him to communicate now using telepathy.
Black-smith published a video On X on his experience with Neuralink, which is told using a replica generated by the AI of the voice of Smith cloned from previous records.
In March, Neuralink filed requests from the American Patent and Brands Office (USPTO) To mark the terms “telepathy”, “blind” and “telekinesis”.
Requests are linked to the offers of Neuralink. Telepathy is a brain interface that aims to allow users to control devices with their thoughts, Blind life is an implant that aims to restore vision in blind individuals and Telekinesis is a term that Musk used interchangeably with telepathy to designate control devices using his mind.
Last year, Neuralink received Health Approval Canada To carry out a clinical trial on its cerebral implant N1 and its robot R1, which is used to place the implant in the brain.
The “Canadian, specifically based on the brain-computer” (Can-Prime) study was carried out by the University Health Network hospital in its Western hospital in Toronto.
Can-Prime has evaluated the company’s security N1 implant security, designed to allow individuals to control a computer or mobile device using their mind and the company’s surgical R1 Robot, used to place each of the 64 threads of the N1 implant in a patient’s brain.